Skip to main content
. 2009 Jun 27;30(18):2233–2240. doi: 10.1093/eurheartj/ehp253

Table 2.

Patient-assessed dyspnoea treatment response by severity of dyspnoea at baseline

Baseline dyspnoea status TLV/PLC, n % improved
Treatment group difference (%) P-value
Tolvaptan Placebo
Seldoma 153/164 71.89 70.12 1.77 0.6934
Frequent 1247/1244 73.62 69.05 4.57 0.0013
Continuous 588/585 75.95 65.65 10.30 0.0021

Note: baseline dyspnoea status determined by investigator. Per cent improved based on patient self-assessment.

aNot included in overall analyses.